2023 Southeastern Section of The American Urological Association (SESAUA)
SESAUA 2023 Prostate Cancer
- SESAUA 2023: State-Of-The-Art Lecture: Advanced Imaging for Prostate Cancer: What’s Changed?
- SESAUA 2023: Clinical Outcomes of Patients With mHSPC With PSA Decline to Undetectable Levels on Enzalutamide: Post Hoc Analysis of ARCHES Trail
- SESAUA 2023: Review of Metastatic Disease Detection and Cost Analysis of Next Generation Imaging Use in Initial Staging of Prostate Cancer
- SESAUA 2023: Long-Term Health Related Quality of Life in Prostate Cancer Patients Requiring Radiotherapy After Radical Prostatectomy
- SESAUA 2023: State-Of-The-Art Lecture: Prostate Biopsy in 2023 – What Should I Know
SESAUA 2023 Upper Tract Urothelial Carcinoma
SESAUA 2023 Bladder Cancer
- SESAUA 2023: Perioperative and New Persistent Opioid Use in Cystectomy Patients
- SESAUA 2023: Oncologic Outcomes: Intravesical Gemcitabine/docetaxel is a Feasible Alternative for Management of High-risk Non-muscle Invasive Bladder Cancer
- SESAUA 2023: A Contemporary Analysis of Treatment of Muscle Invasive Bladder Cancer Using the National Cancer Database: Factors Associated With Receipt of Non-aggressive Therapy
- SESAUA 2023: Patient-Reported Treatment Burden of Intravesical Therapy for Bladder Cancer
- SESAUA 2023: Cisplatin-Ineligible Muscle-Invasive Bladder Cancer Demonstrates Poor Long-term Outcomes Following Immediate Radical Cystectomy: Opportunity For Neoadjuvant Pembrolizumab